Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Gross Margin (2017 - 2025)

Lexaria Bioscience's Gross Margin history spans 9 years, with the latest figure at 100.0% for Q3 2025.

  • For Q3 2025, Gross Margin changed 0.0% year-over-year to 100.0%; the TTM value through Nov 2025 reached 100.0%, up 55.0%, while the annual FY2025 figure was 99.61%, 65.0% up from the prior year.
  • Gross Margin for Q3 2025 was 100.0% at Lexaria Bioscience, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 2718.19% in Q4 2023 and bottomed at 1.89% in Q3 2023.
  • The 5-year median for Gross Margin is 84.08% (2021), against an average of 207.62%.
  • The largest annual shift saw Gross Margin surged 263435bps in 2023 before it plummeted -261967bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 59.87% in 2021, then skyrocketed by 40bps to 83.84% in 2022, then surged by 3142bps to 2718.19% in 2023, then plummeted by -96bps to 98.52% in 2024, then rose by 2bps to 100.0% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Gross Margin are 100.0% (Q3 2025), 100.0% (Q2 2025), and 100.0% (Q1 2025).